MEIP Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...

Stats
Объем за сегодня	8 002.00
Средний объем	21 244.00
Рыночная капитализация	20.32M
EPS	$0 ( 2024-02-08 )
Дата следующего отчета о доходах	( $-1.520 ) 2024-05-09
Last Dividend	$1.750 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	1.020
ATR14	$0.0150 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Flynn James P	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Flynn James P	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
93.13
Last 96 transactions
Buy: 9 932 993 \| Sell: 849 643

MEI Pharma Inc Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

MEI Pharma Inc Финансовые показатели

Annual	2023
Выручка:	$48.82M
Валовая прибыль:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2023
Выручка:	$48.82M
Валовая прибыль:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2022
Выручка:	$40.70M
Валовая прибыль:	$39.46M (96.97 %)
EPS:	$-8.80

FY	2021
Выручка:	$25.54M
Валовая прибыль:	$24.13M (94.49 %)
EPS:	$-0.450

Financial Reports:

No articles found.

MEI Pharma Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

MEI Pharma Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.51 - average (50.95%) | Divividend Growth Potential Score: 0 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.750	2023-11-16
Last Dividend	$1.750	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.750	--
Avg. Dividend % Per Year	11.67%	--
Score	4.75	--
Div. Sustainability Score	5.51
Div.Growth Potential Score	0
Div. Directional Score	2.48	--

Next Divdend (Est)
(2024-04-27)

$3.50 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.75

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.750	35.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.286	1.500	4.27	6.41	[0 - 0.5]
returnOnAssetsTTM	0.265	1.200	1.173	1.408	[0 - 0.3]
returnOnEquityTTM	0.416	1.500	6.49	9.73	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.23	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.644	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.153	-1.500	7.45	-10.00	[0 - 0.6]
interestCoverageTTM	-16.44	1.000	-7.20	-7.20	[3 - 30]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
freeCashFlowPerShareTTM	-7.95	2.00	-3.97	-7.95	[0 - 20]
debtEquityRatioTTM	0.202	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.980	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.63	7.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.40	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.925	0.800	7.17	5.73	[0.5 - 2]
Total Score				5.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.977	1.000	-0.00231	0	[1 - 100]
returnOnEquityTTM	0.416	2.50	7.74	9.73	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.95	2.00	-2.65	-7.95	[0 - 30]
dividendYielPercentageTTM	114.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.729	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-0.560

MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.